C1 Esterase Inhibitor (Berinert)

Berinert is covered for treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adults and pediatric patients when used for an FDA‑approved indication, but is excluded for non‑approved/off‑label compendial uses, must not be combined with other acute HAE agents, and is contraindicated in patients with life‑threatening hypersensitivity to C1 esterase inhibitors. Coverage requires documentation of HAE confirmed by low C4 and low C1‑inhibitor antigenic or functional levels, a request specifically for an acute HAE attack, and acknowledgement/monitoring of thromboembolic and infectious risks (with epinephrine immediately available for hypersensitivity).

"Berinert is indicated for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adults and pediatric patients."

Sign up to see full coverage criteria, indications, and limitations.